Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV)

Trial Profile

Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV)

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Influenza A virus vaccine H2N3 (Primary) ; Influenza A virus vaccine-H9N2 (Primary) ; Influenza virus vaccine live (Primary)
  • Indications Influenza virus infections
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 14 Dec 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 03 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
    • 02 Jan 2013 Actual initiation date (Sep 2012) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top